Vitrolife AB
STO:VITR

Watchlist Manager
Vitrolife AB Logo
Vitrolife AB
STO:VITR
Watchlist
Price: 221.4 SEK 4.04% Market Closed
Market Cap: 30B SEK
Have any thoughts about
Vitrolife AB?
Write Note

Vitrolife AB
Additional Paid In Capital

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Vitrolife AB
Additional Paid In Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Additional Paid In Capital CAGR 3Y CAGR 5Y CAGR 10Y
Vitrolife AB
STO:VITR
Additional Paid In Capital
kr13.5B
CAGR 3-Years
50%
CAGR 5-Years
94%
CAGR 10-Years
51%
Biogaia AB
STO:BIOG B
Additional Paid In Capital
kr1.2B
CAGR 3-Years
0%
CAGR 5-Years
92%
CAGR 10-Years
N/A
Bonesupport Holding AB
STO:BONEX
Additional Paid In Capital
kr1.6B
CAGR 3-Years
0%
CAGR 5-Years
6%
CAGR 10-Years
N/A
Probi AB
STO:PROB
Additional Paid In Capital
kr600.2m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
Additional Paid In Capital
kr17.1B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
BioArctic AB
STO:BIOA B
Additional Paid In Capital
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Vitrolife AB
Glance View

Market Cap
30B SEK
Industry
Biotechnology

Vitrolife AB engages in the development, manufacture, and sale of products and systems for the preparation, cultivation, and storage of human cells, tissue, and organs. The company is headquartered in Goeteborg, Vastra Gotalands and currently employs 427 full-time employees. The company went IPO on 2001-06-26. The Company’s product portfolio comprises G-RINSE, which is a solution for rinsing of contact materials, EmbryoGlue, which is a human albumin recombinant, ASP, which is a solution for oocyte retrieval and rinsing, and Semen VTS, which is a viscosity treatment system, among others. The company also provides a range of procedural solutions for sperm preparation, vitrification, embryo transfer and oocyte retrieval, such as temperature control, condition control, gamete-safe labware and embryo support. The firm is active in Australia, China, France, Italy, Japan, the United States and the United Kingdom, among others, and conducts its business through a number of subsidiaries, such as Vitrolife Ltd., Vitrolife Pty Ltd., and A.T.S. Srl.

VITR Intrinsic Value
139.61 SEK
Overvaluation 37%
Intrinsic Value
Price

See Also

What is Vitrolife AB's Additional Paid In Capital?
Additional Paid In Capital
13.5B SEK

Based on the financial report for Sep 30, 2024, Vitrolife AB's Additional Paid In Capital amounts to 13.5B SEK.

What is Vitrolife AB's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 10Y
51%

Over the last year, the Additional Paid In Capital growth was 0%. The average annual Additional Paid In Capital growth rates for Vitrolife AB have been 50% over the past three years , 94% over the past five years , and 51% over the past ten years .

Back to Top